CDKN2A and sarcoma: As stated in [3], up-regulation/mutation of CDKN2A was detected in numerous cancer forms: neoplasms (squamous cell, ductal, lobular, cystic, mucinous, serous, mesothelial, lipomathous, myomathous, thymic epithelial, complex, mixed), adenomas, adenocarcionmas, gliomas, nevi and melanomas, transitional cell papillomas and carcinomas, mature B-cell lymphomas, soft tissue tumors and sarcomas.